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BRG1-SWI/SNF-dependent regulation of the Wt1
transcriptional landscape mediates epicardial
activity during heart development and disease
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Epicardium-derived cells (EPDCs) contribute cardiovascular cell types during development
and in adulthood respond to Thymosin b4 (Tb4) and myocardial infarction (MI) by reacti-
vating a fetal gene programme to promote neovascularization and cardiomyogenesis. The
mechanism for epicardial gene (re-)activation remains elusive. Here we reveal that BRG1, the
essential ATPase subunit of the SWI/SNF chromatin–remodelling complex, is required for
expression of Wilms’ tumour 1 (Wt1), fetal EPDC activation and subsequent differentiation
into coronary smooth muscle, and restores Wt1 activity upon MI. BRG1 physically interacts
with Tb4 and is recruited by CCAAT/enhancer-binding protein b (C/EBPb) to discrete reg-
ulatory elements in the Wt1 locus. BRG1-Tb4 co-operative binding promotes optimal tran-
scription of Wt1 as the master regulator of embryonic EPDCs. Moreover, chromatin
immunoprecipitation-sequencing reveals BRG1 binding at further key loci suggesting SWI/
SNF activity across the fetal epicardial gene programme. These findings reveal essential
functions for chromatin–remodelling in the activation of EPDCs during cardiovascular
development and repair.
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S
WItch/Sucrose NonFermentable (SWI/SNF) complexes
comprise 11–15 protein subunits and utilize the energy
from adenosine triphosphate (ATP) hydrolysis to slide or
evict nucleosomes1. By reshaping the nucleosome landscape
SWI/SNF complexes may also lead to repression of their target
genes2. BRG1 (Brahma-related gene 1; gene alias SMARCA4) is
the ATPase catalytic subunit of SWI/SNF, although mammals
may also utilize BRM (Brahma; gene alias SMARCA2) as an
alternative catalyst to remodel targeted chromatin2,3. BRG1
contains one bromodomain that recognizes acetylated lysines in
histone tails, facilitating SWI/SNF binding in active enhancers
and near the transcriptional start site (TSS) and, subsequently,
enabling RNA polymerase II (RNAPII) occupancy and
gene transcription1. BRG1 is essential for embryonic
development, while BRM seems to be dispensable due to BRG1
compensation4–6. In the heart, BRG1 is required for endocardium
and myocardium formation7–9, whereas BRM functionally
compensates for BRG1 in the maintenance of adult coronary
vascular endothelial cells10. Of significance, the subunit BAF180
(BRG1-associated factor 180, also known as polybromo protein 1)
specifically forms SWI/SNF complexes containing BRG1 (PBAF
remodelling complexes) and is required for correct cardiac
chamber maturation and epicardial epithelial-to-mesenchymal
transition (EMT). Mice deficient in BAF180 phenocopy cardiac
knockdown of the monomeric-actin binding peptide Tb4
(refs 2,11–13).
The epicardium is the outermost layer of the heart and has
been proposed as a source of cardiovascular regeneration in heart
disease14. During embryogenesis EPDCs play an essential role
contributing interstitial fibroblasts, smooth muscle, endothelial
cells and potentially cardiomyocytes to the growing heart15–17.
Different molecular markers have been employed to follow the
fate of EPDCs including the transcription factors Wt1, Tbx18
(T-box factor 18) and Tcf21 (transcription factor 21), and the
retinoic acid synthetizing enzyme Raldh2 (ref. 18). Wt1 is a zinc
finger-containing transcription factor which functions as the
master regulator of epicardial EMT, a process required for
myocardial growth and coronary vasculature formation19,20. In
this regard, Wt1 sits atop of a hierarchy of embryonic epicardial
gene loci and directly controls the transcription of SnaiI (Snail 1)
and CdhI (epithelial cadherin; e-cadherin)19, and regulates
b-catenin and RALDH2 signalling pathways as required during
epicardial EMT21. The activity of these key developmental genes
is gradually lost during pregnancy, leading to epicardial
quiescence in the postnatal heart, however, Wt1 is up-regulated
in the adult epicardium after MI, an event associated with EPDC
mobilization and differentiation into a default fibroblast fate18,22.
Pre-treatment with Tb4 significantly enhances this epicardial
response, promoting neovascularization and cardiomyogenesis in
the adult injured heart23,24. Even though events downstream of
Wt1 function have been well described, the upstream regulation
of Wt1 activity during either development or adult heart injury
remains unknown.
Here we report an epigenetic mechanism which activates the
transcriptional landscape of Wt1 promoting epicardial activity in
the developing and adult heart after MI. Specifically, we identify a
novel BRG1–SWI/SNF function, implicating chromatin–
remodelling of the Wt1 locus as a critical event in determining
the activation and fate of embryonic EPDCs. Tb4 physically
interacts with BRG1 promoting optimal Wt1 re-expression in the
adult epicardium after MI. The pioneer factor C/EBPb co-
localizes with SWI/SNF complexes to evolutionary conserved
regions (ECRs) of the Wt1 locus located proximal to the TSS and
intron 1, suggesting a potential role in locus-specific recruitment
of the remodelling complex. Co-occupancy by RNAPII, and
association of activating histone modifications, at the Wt1 ECRs
suggests the ECRs are bona fide epicardial regulatory elements. By
making use of transient transgenic systems and combined
reporter-assays, we confirm in vivo the transcriptional activity
of the Wt1 ECRs, which is also augmented by Tb4, further
supporting SWI/SNF-mediated function to be significantly
enhanced by Tb4. Chromatin immunoprecipitation-sequencing
(ChIP-seq) studies reveal BRG1 occupancy at further epicardial
loci, including Raldh2 (gene alias Aldh1a2), Tbx18 and Tcf21,
suggesting a wider role for BRG1–SWI/SNF complexes in the
regulation of epicardial activation. Altogether, these findings
reveal insight into the function of SWI/SNF in regulating the Wt1
transcriptional landscape as an important mediator of EPDC
activity during development and disease.
Results
SWI/SNF catalytic subunits are expressed in the epicardium.
We found that BRG1 and BRM were localized throughout the
developing heart (Fig. 1a,b; Supplementary Fig. 1a–d) and notably
were expressed in the epicardium overlapping with the expression
domain of Wt1 (Fig. 1c; Supplementary Fig. 1b–e). In the adult
heart, BRG1 expression was comparatively reduced in the
myocardium and absent from the quiescent epicardium (compare
Fig. 1a with Fig. 1d; Supplementary Fig. 1a,b). Moreover, BRM
localization was excluded from the epicardium (compare Fig. 1b
with Fig. 1e), which also lacked Wt1 expression, consistent with
the reported down-regulation of the embryonic epicardial
gene program24 (Fig. 1f; Supplementary Fig. 1b). However, in
response to MI, BRG1 and BRM expression in the epicardium
increased (Supplementary Fig. 1f,g), most notably in the
expanded subepicardial region (ses; Fig. 1g,h) and co-localized
with Wt1 re-expression. Wt1 expression was further enhanced
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Figure 1 | BRG1 and BRM are expressed in the developing and adult
epicardium. (a–i) Immunostaining for BRG1, BRM and Wt1 in mouse E11.5
(a–c), adult (d–f) and adult primed- (þTb4), -injured (day 4 post-MI)
hearts (g–i). Arrows mark myocardium, arrowheads mark epicardium and
double-arrow indicates the expansion of the subepicardial space post-MI.
ep, epicardium; my, myocardium; ses, subepicardial space. All scale bars
100 mm.
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Fig. 1i with Supplementary Fig. 1f,h). Taken together, the
spatiotemporal expression of BRG1 and BRM and
colocalization with Wt1, suggests that SWI/SNF complexes may
regulate epicardial Wt1 expression and, subsequently, EPDC
activation. In support of this, EPDCs expressing enhanced GFP
from the Wt1 locus of Wt1GFPCre/þ knock-in mice17 were
positive for BRG1 and BRM, in both the developing and post-MI
adult heart (Supplementary Fig. 1c–h).
SWI/SNF complex binds regulatory elements in the Wt1 locus.
To determine whether SWI/SNF directly regulates Wt1 expres-
sion, we examined BRG1 and BRM binding to the Wt1 promoter
in vivo. Using sequence alignment software (www.dcode.org), we
compared mouse and human genomes to identify evolutionary
conserved regions that may act as sites for SWI/SNF
association7,8 and found seven ECRs in the Wt1 locus, which
were named according to their location in relation to the TSS: two
distal, located upstream of the TSS (starting at E 4.4 kb and
 3.4 kb and extending for 393 bp and 126 bp, respectively), three
proximal, located immediately upstream of the TSS (starting at
E 0.3 kb,  0.2 kb and  42 bp and extending for 101 bp,
129 bp and 439 bp, respectively) and two located within intron 1
(starting atEþ 4.0 kb and þ 5.8 kb and extending for 106 bp and
188 bp, respectively; Fig. 2a; Supplementary Table 1). ChIP on
embryonic hearts with an anti-BRG1 antibody revealed that, of
the seven ECRs, BRG1 was strongly associated with the proximal
promoter ( 42 bp) and intronic (þ 4.0 kb and þ 5.8 kb) ECRs
of Wt1, but not with a non-ECR element (-ECR) localized
upstream of the TSS (starting atE 3.8 kb and extending for
100 bp) confirming specificity of the ChIP signal (Fig. 2b). BRM,
in contrast, only weakly associated with the þ 5.8 kb ECR
(Fig. 2c), whereas BAF180 revealed a similar binding pattern to
BRG1 (Fig. 2d). The co-occupancy patterns observed on Wt1
ECRs could result from transient binding by separate SWI/SNF
components (BRG1 or BAF180) in different subsets of Wt1-
expressing cells, or could be due to a direct interaction between
these proteins. We, therefore, examined potential complex
formation at Wt1 ECRs by sequential ChIP (re-ChIP). Strong
re-ChIP signals were detected with an anti-BAF180 antibody on
BRG1-enriched Wt1 ECRs (Fig. 2b) in hearts at embryonic day
(E) 11.5 (Fig. 2e), confirming SWI/SNF complex formation. In
combination, the ChIP experiments revealed enrichment of SWI/
SNF containing BRG1 and BAF180 in regulatory regions of
murine Wt1 in the embryonic heart, which directly correlated
with epicardial-specific Wt1 expression (Fig. 1c). Moreover, even
though BRM is expressed in the developing epicardium (Fig. 1b),
BRG1 is the preferred ATPase subunit of the SWI/SNF complex
binding at the Wt1 locus.
To investigate whether Wt1 is a direct BRG1–SWI/SNF target
in the adult epicardium, we performed ChIP experiments using
intact (Fig. 2f,g) and injured-adult hearts (Fig. 2h–l). The adult
heart does not ordinarily express Wt1 (Fig. 1f; Supplementary
Fig. 1b) and neither BRG1, nor BRM associated with Wt1 ECRs
in the intact adult heart (Fig. 2f,g), as expected given the lack of
expression of BRG1 and BRM in adult epicardium (Fig. 1d,e).
However, in primed- (þTb4) and injured-adult hearts with
evident Wt1 re-expression at day 4 post-MI (arrowheads in
Fig. 1i), BRG1 had a similar binding pattern to that in the
embryonic heart (compare Fig. 2b,h). BRM was also found to
bind to  42 bp, þ 4.0 kb and þ 5.8 kb ECRs (Fig. 2i), in contrast
to the lack of binding in embryonic hearts and suggesting that in
the reactivated adult epicardium BRM may act redundantly
with BRG1 to regulate Wt1 expression. By contrast, in
non-primed-, injured-adult hearts that exhibited low levels of
Wt1 at day 4 post-MI (arrowheads in Fig. 2l) there was minimal
association of BRG1 and BRM to Wt1 ECRs (Fig. 2j,k), even
though BRG1 and BRM were expressed (Supplementary
Fig. 1b,f,g). Overall, these data demonstrate the existence of
ECRs in the Wt1 locus that are bound by SWI/SNF complexes
containing BRG1 or BRM (adult epicardium only) as the catalytic
subunit. Occupancy at these ECRs dynamically alters during
embryogenesis into adulthood and responds to exogenous Tb4
and injury, suggesting that chromatin–remodelling of the Wt1
locus by SWI/SNF is amplified by Tb4 and directly associates
with enhanced Wt1 and epicardial activity23,24.
To further characterize the remodelling of the Wt1 locus in the
developing and adult heart, we investigated the association of the
 42 bp, þ 4.0 kb and þ 5.8 kb ECRs, with RNAPII and
canonical epigenetic modifications in histone H3 tails, previously
implicated in gene activation and repression: K4me1, K4me3,
K27ac and K27me3 (ref. 25). When Wt1 was ‘off’ (that is, intact
adult heart) the repressive H3K27me3, catalysed by the Polycomb
complex 2 (PRC2)26, was the only epigenetic mark found to
significantly associate to  42 bp, þ 4.0 kb and þ 5.8 kb ECRs
(compare Supplementary Fig. 2e with Supplementary Fig. 2a–d;
Pr0.05 for the three Wt1 ECRs; the two-tailed Student’s t-test
was used to determine the statistical significance). In contrast,
when Wt1 was ‘on’ (that is, embryonic and primed-, injured-adult
hearts) RNAPII phosphorylated at serine five (confined to
promoter regions and required for the initiation of
transcription27), was enriched in  42 bp and þ 4.0 kb ECRs
(Supplementary Fig. 2f), suggesting that these elements act as
bona fide regulatory elements of gene expression. Moreover,
H3K4me1 (associated with putative enhancers) was enriched in
þ 4.0 kb and þ 5.8 kb ECRs (Supplementary Fig. 2g), whereas
H3K4me3 (associated with active promoters) was enriched in all
three Wt1 ECRs (Supplementary Fig. 2h). Finally, while the
activating histone mark H3K27ac (associated with TSS and active
enhancers) was strongly enriched in  42 bp and þ 4.0 kb ECRs
(Supplementary Fig. 2i), the counteracting, mutually exclusive
modification H3K27me3 (associated with inactive promoters)
was also detected in the three ECRs (Supplementary Fig. 2j),
suggesting differences in the epigenetic remodelling of the Wt1
locus, which likely reflects the dynamic changes in spatiotemporal
expression. Of note, when Wt1 activation is ‘low’ (that is,
non-primed, injured-adult hearts) a similar epigenetic profile was
observed on Wt1 ECRs (Supplementary Fig. 2k–o), suggesting
that cardiac injury alone, which leads to minimal association of
BRG1 and BRM to Wt1 ECRs (Fig. 2j,k), is sufficient to induce
remodelling of the Wt1 locus and subsequent low level Wt1
re-expression (Fig. 2l), however, this is suboptimal when
compared with ectopic Tb4 treatment (Fig. 1i).
C/EBPb recruits the SWI/SNF complex into the Wt1 locus.
Targeting of the SWI/SNF complex to the Wt1 locus within the
epicardium is likely mediated by sequence-specific transcription
factors, which access silent chromatin and initiate cell specific
gene activation through recruitment of chromatin–remodelling
complexes and co-activator partners3. To this end, the pioneering
C/EBPs have been shown to mediate epicardial gene activation
during heart development and injury28. In addition, the C/EBPb
isoform has been shown to recruit the SWI/SNF complex to
specific genomic loci, via direct interaction with BRG1 (ref. 29).
In silico analysis of Wt1  42 bp, þ 4.0 kb and þ 5.8 kb ECR
sequences predicted the existence of C/EBPb binding sites
(Supplementary Table 2), raising the possibility that C/EBPb
may recruit SWI/SNF complexes containing BRG1 to the Wt1
ECRs. To explore this further, we performed ChIP with an anti-
C/EBPb antibody and observed enrichment of C/EBPb in all
three ECRs in fetal and primed-, injured-adult hearts
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(Supplementary Fig. 3a–d). Subsequent re-ChIP analyses with an
anti-BRG1 antibody confirmed complex formation between
C/EBPb and BRG1 on Wt1 ECRs (Supplementary Fig. 3b,d).
Furthermore, siRNA-targeting of C/EBPb transcripts resulted in
decreased expression of Wt1 and the Wt1-downstream target
gene Raldh2 (ref. 21) in mouse primary epicardial cells
(Supplementary Fig. 3e,f), supporting a role for a C/EBPb-SWI/
SNF remodelling complex in the regulation of Wt1 ECRs.
Wt1 ECRs drive epicardial gene expression in vivo. To obtain
in vivo evidence of Wt1 ECR activity, we employed an established
transient transgenic enhancer reporter assay30 to engineer Wt1
ECR-LacZ mice and observed robust b-galactosidase (b-gal)
activity. The reporting of individual Wt1 ECR activity lacks
cooperative interaction with cis-acting elements (enhancers or
negative regulatory regions) as would be associated with the intact
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Figure 2 | ATP-dependent SWI/SNF complexes bind ECRs in the Wt1 locus. (a) Sequence alignment of the Wt1 locus from mouse and human. Peak
heights indicate degree of sequence homology; pink bars above the peaks denote evolutionary conserved regions (ECRs); yellow represents the 50
untranslated region (UTR); blue indicates exon 1. Boxed regions were selected for further analysis by ChIP. Numbers above boxed regions denote ECR
approximate distances upstream ( ) or downstream (þ ) of the transcription start site (TSS). (b–d) ChIP-qPCR data using chromatin derived from
embryonic hearts at E11.5 and anti-BRG1, anti-BRM or anti-BAF180 antibodies. Note that no enrichment was detected in non-ECR elements (( )ECR)
confirming ChIP signal specificity. (e) Sequential ChIP (re-ChIP) with an anti-BAF180 antibody using embryonic heart-derived chromatin pulled-down with
anti-BRG1. (f,g) ChIP-qPCR data using chromatin derived from adult intact (no MI) hearts and anti-BRG1 or anti-BRM antibodies. (h,i) ChIP-qPCR data
using chromatin derived from adult primed- (þTb4), injured-hearts at day 4 post-MI and anti-BRG1 or anti-BRM antibodies. (j,k) ChIP-qPCR data using
chromatin derived from adult non-primed, injured-hearts at day 4 post-MI and anti-BRG1 or anti-BRM antibodies. (l) Wt1 immunostaining in post-MI adult
hearts showing expanded subepicardial space (indicated by double-arrow), but weak re-expression of Wt1 in the epicardium (arrowhead). Three
independent experiments per antibody were performed using 20 hearts at E11.5 and three adult hearts per experiment. ChIP results are presented as fold
enrichment over input, whereas re-ChIP results are present in fold enrichment over the level of ChIP with negative control IgG antibody. All error bars are
data±s.d. Significant differences (P values) were calculated using two-tailed Student’s t-test (*Pr0.05; **Pr0.01). bp, base pairs; kb, kilobases; my,
myocardium; ses, subepicardial space. Scale bar 100 mm.
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be expected to precisely mimic endogenous gene expression and
instead overlap in-part with Wt1 in the developing embryo31,32
(Fig. 3a–i; Supplementary Figs 4,5). The  42 bp ECR, which
based on its genomic location (Fig. 2a) is predicted to act as a Wt1
core promoter, recapitulated at least some of the regions of Wt1
expression (Supplementary Fig. 5), and importantly drove b-gal
activity strongly throughout the epicardium covering the
developing ventricles, atria and outflow tract (arrowheads and
arrows, respectively in Fig. 3a,b; Supplementary Figs 4,5). The
observed expression in the outflow tract was considerably
elevated and regionally expanded relative to the corresponding
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Figure 3 | Wt1 ECRs drive gene expression and BRG1 is required for EPDC activity. (a–i) Wt1 ECRs are sufficient to drive LacZ expression in the
epicardium at E11.5. Whole-mount (a,c,e,f,h) and transverse-sectioned hearts (b,d,g,i) are shown. Arrowheads mark epicardium covering the ventricles;
arrows mark epicardium covering the atria (a,b) and outflow tract (a). Two (42 bp), five (þ4.0 kb) and six (þ 5.8 kb) transgenic mice were examined to
assess the reproducibility of reporter activity patterns. (j–s) BRG1 and Wt1 immunostaining of E11.5 hearts documenting Brg1 deletion (asterisks in l,q) and
Wt1 reduction (asterisks in m,r) in the epicardium of Brg1 cKOs compared to littermate controls (arrowheads in j,k and o,p). Note reduced BRG1 expression
also in the myocardium (arrows; compared j with l versus o with q) of Gata5Cre;Brg1flox/flox, but not Wt1CreERT2;Brg1flox/flox hearts. (n,s) BRG1 ChIP-qPCR data.
Three independent ChIP experiments were performed per group (n¼ 10 hearts) and are presented as fold enrichment over IgG. (t,u) Wt1 immunostaining
of E16.5 hearts documenting fewer Wt1-positive cells in the epicardium (arrowheads) and EPDCs invading the subepicardial and myocardial layers (arrows)
in Brg1 cKOs. Note magnified views of (red) inset boxes in t and u. (v) Quantification of Wt1-expressing cells in E16.5 hearts as %¼ (total number of Wt1-
positive cells per section/total number of DAPI nuclei per section) 100; co, n¼ 3 hearts; mut, n¼4 hearts. (w,x) Endomucin (EMCN) and smooth-
muscle myosin heavy chain 11 (SM-MHC) immunostaining of E16.5 hearts documenting a reduction of patent coronary vessels, containing endothelium
(arrow) surrounded by smooth muscle (arrowheads), in Brg1 cKOs hearts. Note magnified views of (red) inset boxes in panels w and x. (y) Quantification
of patent vessels per field in E16.5 hearts; 6 fields analysed per section per genotype; co, n¼ 3 hearts; mut, n¼4 hearts. All error bars are data±s.d.
Significant differences (P values) were calculated using two-tailed Student’s t-test (*Pr0.05; **Pr0.01; ***Pr0.001). co, control; ep, epicardium; la, left
atrium; lv, left ventricle; mut, mutant; my, myocardium ra, right atrium; rv, right ventricle; v, ventricle. All scale bars 200mm, except j,o,t,u,w,x 100mm and
magnified views of inset boxes in t,u,w,x 20mm.
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absence of cis-acting repressive elements present in the
Wt1-locus. Elsewhere in the developing embryo, the  42 bp
ECR drove b-gal activity strongly in domains of the spinal cord
and brain (arrows in Supplementary Fig. 4a and Supplementary
Fig. 5), where lateral motor neurons expressing Wt1 are being
formed32, and the mesothelium of the body wall and gut, which
represent further sites of known Wt1 expression32 (arrow in
Supplementary Fig. 4b; Supplementary Fig. 5). The activity of the
more distal, intronic þ 4.0 kb (Fig. 3c,d; Supplementary
Fig. 4d–f) and þ 5.8 kb (Fig. 3e–g; Supplementary Fig. 4g–i)
ECR transgenes was relatively weaker, when compared to the core
promoter element ( 42 bp ECR), and restricted to epicardial cell
clusters. Of note, the þ 5.8 kb ECR transgene also drove b-gal
activity in the urogenital region (Supplementary Fig. 4j-l), where
Wt1 plays a pivotal role in development31. In the absence of
ECR-LacZ transgene integration, no b-gal activity was observed
confirming signal specificity (Fig. 3h,i).
BRG1 is required for activation of the Wt1 locus. We next
tested whether BRG1 plays an essential role in Wt1 regulation.
We first used siRNA to specifically knock-down Brg1 in mouse
primary epicardial cells and observed reduction in the expression
of Wt1 and Raldh2 (Supplementary Fig. 6a,b). Subsequently,
we used Gata5Cre and Wt1CreERT2 Cre-drivers crossed with a
Brg1flox/flox mouse line17,33–35 to conditionally delete Brg1 in the
mouse epicardium by E11.5 and examined Wt1 expression
(Fig. 3j–r; Supplementary Fig. 6c,d). Both Cre strains induced
reduction of Brg1 levels in the developing heart. Gata5Cre was
relatively more efficient (Supplementary Fig. 6c), however, this
was explained by Gata5Cre targeting Cre activity additionally in
non-epicardial cells (Supplementary Fig. 6e,f), such that BRG1
was reduced in the developing endocardium/myocardium and
epicardium as compared to Wt1CreERT2 targeting, which was
epicardial-specific, albeit with variable efficiency (compare
Fig. 3j,l with Fig. 3o,q). Notably, targeting of Brg1 led to
decreased Wt1 and Raldh2 expression in mutant hearts,
compared to control littermates (Fig. 3k,m,p,r; Supplementary
Fig. 6d). Moreover, reduced Wt1 expression was strongly
associated with reduced binding of BRG1 to Wt1 ECRs in
Brg1-deficient hearts (Fig. 3n,s), further supporting that BRG1-
occupancy is required for Wt1 activity during murine epicardial
development.
To determine the functional consequences of deleting Brg1 in
the developing epicardium, we extended the phenotypic analysis
of Brg1-deficient embryos to E16.5 and assessed EPDC mobiliza-
tion and accompanying coronary smooth muscle differentiation20
(Fig. 3t–y; Supplementary Fig. 6g–p). No live embryos positive for
the Gata5Cre allele and bearing two copies of the Brg1 floxed
alleles (Gata5Cre; Brg1F/F: Mut) were collected at E16.5; indeed
harvesting of embryos at earlier developmental stages revealed
that Brg1 mutants died between E12.5 and E16.5 (Supplementary
Fig. 6g). At E12.5, mutant hearts exhibited lower levels of
coronary smooth muscle markers compared to littermate controls
(Co) (Supplementary Fig. 6h), including SM22a (smooth muscle
protein 22-alpha) and SMAa (smooth muscle actin, alpha). In
addition, endothelial/endocardial markers (Supplementary
Fig. 6i) such as platelet and endothelial cell adhesion molecule
1 (PECAM) and the tyrosine-protein kinase receptor Tie2, and
myocardial markers (Supplementary Fig. 6j), such as the myosin
heavy chain polypeptides a and b (aMHC and bMHC,
respectively), were also reduced in mutants, reflecting Cre
activity and the requirement for Brg1 in both epicardial and
non-epicardial compartments (Supplementary Fig. 6e). Moreover,
histological characterization of transverse sections from mutant
hearts revealed under-developed and disorganized chamber walls,
with no clear ventricular septation and dilated atria (compare
Supplementary Fig. 6k with 6l). The severity of these cardiac
malformations is likely to induce embryonic lethality, preventing
the examination of patent coronary vasculature at E16.5. Rare
surviving mutants, collected at E14.5 (n¼ 8 out of 73 embryos)
and E15.5 (n¼ 1 out of 16 embryos), revealed small, under-
developed hearts (Supplementary Fig. 6m,n), a lack of Wt1-
positive epicardial cells and a disorganized endomucin (EMCN)-
positive endocardium/endothelium (Supplementary Fig. 6o,p),
respectively. Consequently, in order to address the functional
consequences of epicardial deletion of Brg1 on EPDC activity at
later stages of embryogenesis, we focused our studies on the
characterization of mutant embryos generated using the
epicardial-specific Wt1CreERT2 Cre-driver. Wt1-derived Cre
activity was induced by tamoxifen delivery to delete Brg1 from
E10 and while mutant embryos collected at E16.5 appeared
grossly normal, immunostaining revealed a reduction in the
number of Wt1-positive cells located in the epicardium or
invading the subepicardial space and adjacent myocardial layer
(arrowheads and arrows, respectively in Fig. 3t,u), which was
statistically significant when compared to littermate control
hearts (Fig. 3v; Pr0.001; the two-tailed Student’s t-test was
used to determine the statistical significance). Additional
immunostaining studies using antibodies against the coronary
smooth muscle marker SM-MHC (smooth muscle-myosin heavy
chain polypeptide 11) and endothelial marker EMCN, showed a
dramatic decrease in the number of patent coronary blood vessels
(an endothelial layer surrounded by supporting smooth cells) in
embryos positive for the Wt1CreERT2 allele and bearing two copies
of the Brg1 floxed alleles (Wt1CreERT2; Brg1F/F: Mut; Fig. 3w–y),
further confirming the requirement for Brg1-mediated regulation
of EPDC activity in the developing heart.
Tb4 interacts with BRG1 augmenting Wt1 activation post-MI.
Collectively our data revealed that the SWI/SNF complex
promotes Wt1 activity in the developing and adult epicardium,
via binding of its catalytic subunit at three discrete cis-regulatory
elements in the Wt1 locus. Moreover, SWI/SNF-mediated
function is enhanced by stimulation with exogenous Tb4 before
MI. Insight into how Tb4 amplifies SWI/SNF chromatin–
remodelling emerged with the identification of BRG1 as a
potential binding partner of Tb4 via a yeast two-hybrid (Y2H)
screen using a mouse embryonic complementary DNA (cDNA)
library as prey and Tb4 as bait to identify molecular interactors.
To validate the Y2H finding, we performed co-immunoprecipi-
tation experiments, between EGFP-tagged Tb4 and endogenous
BRG1 (Fig. 4a,b). Tb4-EGFP co-immunoprecipitated with BRG1,
but not with the control IgG indicating specificity of binding
(Fig. 4a). Moreover, subsequent immunoblotting for BRG1
confirmed successful immunoprecipitation of the ATPase subunit
by the anti-BRG1 antibody (Fig. 4a). Reciprocal co-immunopre-
cipitation experiments, using an anti-Tb4 antibody for pull-down
with anti-BRG1 and anti-GFP antibodies for immunoblotting,
further confirmed physical interaction between BRG1 and Tb4
(Fig. 4b). Tb4 is expressed in the developing and adult injured
heart, including the epicardium (Supplementary Fig. 1e,h;
Supplementary Fig. 7a–c), in an equivalent spatiotemporal
pattern to BRG1 supporting a potential protein–protein
interaction. To probe a physical association between BRG1 and
Tb4 in vivo, we performed Duolink II in situ proximity ligation
assay (PLA) with specific PLUS and MINUS PLA probes against
BRG1 and Tb4 antibodies in embryonic and postnatal hearts
(Fig. 4c–e). Nuclear PLA positive signals (red ‘speckles’) were
present in myocardial and epicardial cells in the developing heart
(arrow and arrowheads, respectively in Fig. 4c) and in the
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expanded subepicardial space upon injury (arrowheads in
Fig. 4e), but not in the intact adult heart (Fig. 4d). This result was
in agreement with the expression pattern of BRG1 (Fig. 1a,d,g).
To test the specificity of the nuclear PLA signals both a positive
control with BRG1 and BAF155 (another subunit of the SWI/SNF
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Figure 4 | Tb4 interacts with SWI/SNF enhancing activation of the adult epicardium. (a,b) Immunoprecipitation experiments with Tb4-EGFP-
transfected cells using anti-BRG1 (a) or anti-Tb4 (b) antibodies. The original uncropped images of gels are shown in Supplementary Fig. 11. (c–e) Duolink
in situ analysis using anti-rabbit PLUS and anti-mouse MINUS PLA probes specific for Tb4 and BRG1 antibodies respectively, in embryonic (c), intact adult
(d) and post-MI hearts (e). (f–h) Duolink in situ analysis using anti-rabbit PLUS and anti-mouse MINUS PLA probes against BRG1 and BAF155. (i–k) re-ChIP
with anti-Tb4, anti-BAF180 or anti-BRG1 antibodies using chromatin pulled-down with anti-BRG1 (i,j) or anti-BRM (k) to examine Tb4-SWI/SNF complex
formation in E11.5 (i) and adult post-MI, primed hearts (j,k). (l) ChIP-qPCR data from chromatin derived from post-MI, Tb4 knockout (KO) adult hearts
showing minimal binding of BRG1 in Wt1 ECRs. (m) Wt1 and Raldh2 expression analysis by qRT-PCR compared to sham-operated animals. (n) ChIP-qPCR
data from chromatin generated from primed- (þTb4), and injured- (MI) adult Tb4 knockout hearts revealing BRG1 strong enrichment in Wt1 ECRs.
(o) Wt1 and Raldh2 expression analysis by qRT-PCR compared to sham-operated animals. At least three independent ChIP experiments per antibody per
sample group (n¼ 10 fetal hearts; n¼ 3 adult hearts) were performed. ChIP results are presented as fold enrichment over input, whereas re-ChIP results
are present in fold enrichment over the level of ChIP with negative control IgG antibody. (p) List of representative BRG1-enriched epicardial genes shared
between PBS- and Tb4-primed, -injured (MI) adult hearts and representative UCSC browser snapshots of the Aldh1a2 and Tbx18 loci (highlighted in blue in
the list of genes) derived from the Brg1 ChIP-seq experiments. All error bars are data±s.d. Significant differences (P values) were calculated using
two-tailed Student’s t-test (*Pr0.05; **Pr0.01). ep, epicardium; my, myocardium; ses, subepicardial space. All scale bars 50mm.
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Supplementary Fig. 7d–f) antibodies (Fig. 4f–h) and negative
controls with Tb4 and BRG1 antibodies on their own
(Supplementary Fig. 7g,h) or BRG1 and Tb4 antibodies on Tb4
knockout samples (Supplementary Fig. 7i) were included. Similar
to BRG1 and Tb4, nuclear BRG1 and BAF155 PLA signals were
detected exclusively in the myocardium and epicardium of both
embryonic and post-MI hearts, confirming the presence of
functional SWI/SNF chromatin–remodelling complexes (arrow
and arrowheads in Fig. 4f,h). Further confirmation of an
interaction between Tb4 and the SWI/SNF catalytic subunit was
obtained in vivo by re-ChIP analyses (Fig. 4i,j). Robust re-Chip
signals were detected with an anti-Tb4 antibody on BRG1-enri-
ched Wt1 ECRs in embryonic (Fig. 4i) and adult
primed- (þTb4), injured- hearts (Fig. 4j). Of note, the latter
BRG1-enriched elements were also enriched for BAF180 (Figs 2e
and 4j), confirming the formation of SWI/SNF complexes
containing Tb4, BRG1 and BAF180 in epicardial cells. Likewise,
re-ChIP experiments using BRM-enriched Wt1 ECRs revealed
that BRM interacts with Tb4, but not BRG1 in primed-,
injured-adult hearts (Fig. 4k), resulting in the formation of
Tb4–BRM–SWI/SNF complexes in the adult reactivated
epicardium. Re-ChIP experiments using BRM-enriched Wt1
ECRs at E11.5 were not possible due to the low binding of BRM
in the Wt1 locus (Fig. 2c).
Following our observations that Tb4 priming enhanced
SWI/SNF-mediated activation of Wt1 in the adult epicardium
(Fig. 1i versus Fig. 2l; Fig. 2h,i versus Fig. 2j,k; Supplementary
Fig. 1b), we tested whether endogenous levels of Tb4
(Supplementary Fig. 7b,c) were sufficient to promote SWI/SNF
complex activity. Tb4 knockout mice, followed by MI, revealed a
modest increase in SWI/SNF-binding Wt1 ECRs and associated
increase in Wt1 expression during heart injury (Fig. 4l,m; also in
development, Supplementary Fig. 8), however, priming with
exogenous Tb4 in Tb4 knockout mice, followed by MI, resulted
in significantly enhanced binding of the SWI/SNF complex to
Wt1 ECRs augmenting Wt1 reactivation (Fig. 4n,o). This
suggested that endogenous Tb4 is dispensable for optimal SWI/
SNF binding and reinforced a functional requirement for ectopic
(exogenous) Tb4 priming in nuclear targeting of SWI/SNF-
mediated regulation of Wt1. To further investigate the role of Tb4
in SWI/SNF transcriptional activation of Wt1, we cloned the Wt1
ECRs into a chromatinized episomal reporter, pREP4 (ref. 36),
and transfected the constructs into the human cell line SW13 that
lacks BRG1 and BRM, but expresses all other SWI/SNF
components8,37. SW13 cells were transfected with luciferase
reporters ( 0.2 kb-luc,  42 bp-luc, þ 4.0 kb-luc or þ 5.8 kb-
luc) and either BRG1/BRM/Tb4 alone or Tb4 in combination
with BRG1 or BRM expression constructs. A myc-tagged Tb4
construct, carrying a nuclear localization signal (NLS-Tb4-myc),
was used to drive Tb4 into the nucleus. Restoring BRG1
expression to SW13 cells resulted in a significant increase in
activity of all Wt1 ECR reporters, with the only exception being
the  0.2 kb ECR (Supplementary Fig. 9;  0.2 kb-luc:
1.085±0.13 versus  42 bp-luc: 1.211±0.14; þ 4.0 kb-luc:
1.359±0.11; and þ 5.8 kb-luc: 1.430±0.20; P r0.001
( 42 bp-luc), Pr0.0001 (þ 4.0 kb-luc) and Pr0.01 (þ 5.8 kb-
luc); one-way analysis of variance (ANOVA) followed up by
Tukey’s multiple comparison test was used for comparing three
or more groups). A lack of activity at the  0.2 kb ECR was
anticipated given that no BRG1 binding was detected for this
element, suggesting that it does not convey any regulatory
function. Restoring BRM expression also resulted in a significant
increase in þ 4.0 kb-luc and þ 5.8 kb-luc reporter activity
(Supplementary Fig. 9; 1.241±0.07 and 1.376±0.06,
respectively, P r0.01 (þ 4.0 kb-luc) and Pr0.05 (þ 5.8 kb-
luc). Tb4 expression alone did not induce Wt1 ECR reporter
activity (Supplementary Fig. 9), however, co-expression of BRG1
or BRM with Tb4 significantly increased  42 bp, þ 4.0 kb and
þ 5.8 kb-luc reporter activity over BRG1, BRM and Tb4 alone
(Supplementary Fig. 9;  42 bp-luc: 1.406±0.12 (BRG1þTb4)
and 1.175±0.19 (BRMþTb4) versus 1.211±0.14 (BRG1) and
1.055±0.06 (BRM), Pr0.001 for both ECR-luc; þ 4.0 kb-luc:
1.646±0.238 (BRG1þTb4) and 1.578±0.11 (BRMþTb4)
versus 1.359±0.11 (BRG1) and 1.241±0.07 (BRM), Pr0.001
and Pr0.0001 respectively; þ 5.8 kb-luc: 1.887±0.414
(BRG1þTb4) and 1.684±0.215 (BRMþTb4) versus
1.430±0.20 (BRG1) and 1.376±0.06 (BRM), Pr0.01 and
Pr0.05 respectively; one-way ANOVA followed up by Tukey’s
multiple comparison test was used for comparing three or more
groups). These results are in line with our in vivo observations
(Fig. 4l–o) and support direct activation of Wt1 ECRs by
SWI/SNF complexes containing Tb4.
A role for BRG1-SWI/SNF in global gene activation. To
investigate whether the role for BRG1–SWI/SNF complexes is
restricted to the Wt1 locus, or whether they might regulate other
epicardial loci, we employed ChIP-seq to perform a comparative
analysis of the binding of BRG1 in PBS- versus Tb4-primed,
injured- (MI) adult hearts (Fig. 4p; Supplementary Fig. 10).
Among the shared genes, between PBS- and Tb4-primed,
injured-adult hearts, we identified binding at Wt1, confirming our
targeted ChIP-qPCR data, and at other fetal epicardial loci such
as Tbx18, Aldh1a2 and Tcf21 (Fig. 4p). BRG1 binding was also
evident at adult epicardial genes (Fig. 4p) previously identified in
a transcriptomic study of the adult murine epicardium38,
including the membrane proteins uroplakin 3b (Upk3b),
uroplakin 1b (Upk1b), glycoprotein m6a (Gpm6a) and the
transcription factor basonuclin-1 (Bcn1). In addition, key
myocardial genes Myh6 (also known as aMHC) and Myh7 (also
known as bMHC), encoding for myosin heavy chains alpha and
beta, respectively, and other cardiac-related genes, such as Col1a2
(collagen 1 alpha-2, a fibroblast marker) and Acta2 (also known
as SM actin, alpha 2, a smooth muscle marker), were also
represented in the list of shared BRG1-enriched genomic regions
(Supplementary Fig. 10), suggesting novel gene-regulating
functions for the SWI/SNF chromatin–remodelling complex in
the (adult) injured heart. Of significance, the expression of some
of these genes (for example, aMHC and bMHC) was found to be
decreased upon Gata5Cre-mediated deletion of Brg1 in the
developing non-epicardial compartment (Supplementary
Fig. 6h,j), in agreement with the hypothesis that the function of
the SWI/SNF chromatin–remodelling complex in the developing
heart is recapitulated in the adult injured heart7. To validate the
genomic binding of BRG1, we analysed the ChIP-seq profile in
already described sites of SWI/SNF occupancy, such as our
intronic þ 4.0 kb ECR within the Wt1 locus (Fig. 2) and the 5 kb
region upstream of the Myh7 TSS7. While Brg1-binding was
detected in these regions in both PBS- and Tb4-primed, -injured
samples, considerably more peaks were observed in the
Tb4-primed sample set (Supplementary Fig. 10). Likewise,
BRG1 peak density was comparatively higher in epicardial loci
such as Tcf21, Upk3b and Tbx18 and cardiac-related loci such as
Acta2 in the Tb4-primed, -injured sample set versus the non-
primed (PBS) group (Fig. 4p; Supplementary Fig. 10). As such, we
speculate that Tb4 may play a role in amplifying BRG1-targeting
of downstream embryonic epicardial loci, as important for
inducing the reactivation of EPDCs following adult heart
injury. Taken together, our ChIP-seq data supports BRG1–SWI/
SNF binding of Wt1 and suggests a role for chromatin–
remodelling in activation of further key epicardial genes, such
as Tbx18 and Tcf21.
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Discussion
Here we reveal that epicardial activity is epigenetically regulated
during development and adult heart injury and that Wt1, the
master regulator of epicardial EMT, is dynamically controlled by
SWI/SNF chromatin–remodelling complexes containing BRG1
and Tb4 (Figs 1–4). Tb4 lacks a DNA-binding domain, but
physically interacts with SWI/SNF (Fig. 4) and serves to augment
BRG1 and BAF/BRG1 binding at specific enhancer sites within
the Wt1 locus (Figs 2 and 4). BRG1, as the preferred SWI/SNF
ATPase subunit, was essential to maintain Wt1 expression and
associated EPDC activity (Fig. 3). Tb4–SWI/SNF contained the
epicardial-specific pioneer transcription factor C/EBPb
(Supplementary Fig. 3), which likely functions to target the
complex to the Wt1 locus. Tb4-BRG1 binding may be mediated
via nuclear actin as an essential component of the SWI/SNF
complex which, along with the BAF53 subunit, tightly binds
BRG1 to regulate its ATPase activity39. Given the high affinity of
Tb4 for monomeric G-actin40 and previous reports of
co-localization of Tb4 with actin in the nucleus41,42 it is
possible that Tb4 interacts with BRG1 through provision of
essential G-actin for complex formation and chromatin
remodelling activity; although an actin-independent role for
Tb4 cannot be excluded at this stage.
The reactivation of embryonic genes is a hallmark of attempts
by the adult heart to compensate for cardiovascular stress and
disease. This includes pathologic hypertrophy which is associated
with the up-regulation of a signature fetal gene program43. BRG1
is reactivated in the adult myocardium in response to cardiac
stress and forms a complex with its embryonic partners, HDACs
(histone deacetylases) and PARP (poly ADP ribose polymerase),
to induce a-myosin heavy chain (MHC) to b-MHC switch7. Fetal
gene re-expression, in this setting, is insufficient to counteract
the pathology and suppress adverse remodelling and is unable to
instigate a regenerative response. There is a requirement,
therefore, for amplification of the epigenetic effector signals
and to elicit targeting to key loci, upstream of multiple
developmental pathways. In this regard, the relative levels of
Tb4 appeared to be critical for efficient SWI/SNF complex
activity and Wt1 expression (Figs 1, 2 and 4), which likely sits
upstream of EPDC activation and cell fate. This was particularly
relevant in the context of reactivation of the adult epicardium
upon myocardial injury (Figs 2 and 4), whereby ectopic Tb4
priming resulted in optimal activation of SWI/SNF-enhanced
reactivation of EPDCs (Figs 2 and 4) and subsequent
differentiation into coronaries and muscle23,24; while injury
alone (despite inducing an up-regulation of endogenous Tb4
expression) resulted in minimal SWI/SNF activation (Fig. 2) of
EPDCs24,44, which subsequently adopts a default fibroblast
differentiation program22. ChIP-seq revealed an extensive
range for Tb4–BRG1–SWI/SNF activity following adult cardiac
injury at additional epicardial and cardiac gene loci (Fig. 4).
Further studies will be required to dissect the functional
implications of promiscuous BRG1–Tb4 activity in the context
of promoting adult cell activation, in light of our previous
findings that Tb4 treatment prior to MI facilitates improved
heart repair2. Epigenetic induction, with co-factor amplification,
of fetal genes to activate adult progenitor populations may
represent a general paradigm in cell-based tissue repair. More
specifically, targeting dynamic chromatin signatures at key
embryonic genes that underlie epicardial cell activation could
represent a therapeutic strategy to regenerate the injured-adult
mammalian heart.
Methods
Animal models. All animal experiments were carried out according to UK Home
Office project Licence PPL30/2987 compliant with the UK animals (Scientific
Procedures) Act 1986 and approved by the local Biological Services Ethical Review
Process. Mice were housed and maintained in a controlled environment. Gata5Cre,
Tb4 / , Wt1GFPCre, Wt1CreERT2, Brg1flox/flox and R26RtdTomato mice were kept in
a C57Bl/6J inbred background17,33–35,45,46. For timed mating experiments, 8–12
week old mice were set-up overnight and females checked for vaginal plugs the
following morning; the date of a vaginal plug was set as embryonic day (E) 0.5. For
tamoxifen-dependent tissue-specific gene inactivation using the Wt1CreERT2 driver,
2 mg of 4-hydroxytamoxifen (Sigma) were administered to pregnant mice by
intraperitoneal (i.p.) injection at both E9.5 and E10.5 to maximize Cre-ERT2
activity in the developing epicardium.
Thymosin b4 administration. The injection regimen of Tb4 for priming of wild-
type C57BL/6J, Tb4 / and Wt1GFPCre/þ mice have been previously described24.
Briefly, adult mice received i.p. injection of clinical grade Tb4 (12 mg/kg;
RegeneRex Biopharmaceuticals Inc.) or vehicle (PBS) daily for 7 days. On the
eighth day, MI was performed and further injections of Tb4/vehicle were given on
day 0 and day 2 post surgery.
Myocardial infarction. All surgical and pharmacological procedures were per-
formed in accordance with the Animals (Scientific Procedures) Act 1986 (Home
Office, UK). For MI experiments, adult mice (12–14 week old; 25–30 g body
weight) were primed with Tb4 or vehicle, as described above, before surgical
procedures. MI was induced in isoflurane-anaesthetized mice by permanent liga-
tion of the left anterior descending coronary artery (LAD). For sham controls, a
suture was passed under the LAD but not ligated. Upon recovery (day 0), animals
received i.p. injection of Tb4 (12 mg kg 1) or vehicle (PBS). Further injections
were given every second day. Hearts were harvested at 4 days following ligation.
Immunodetection methods. Cryosections were processed for indirect immuno-
fluorescence using standard methods. AlexaFluor secondary antibodies (Invitrogen,
1:200) were used in all cases. Where mouse primary antibodies were used, 1 h
incubation with AffiniPure Fab Fragment Goat Anti-Mouse IgG (Jackson Immu-
noResearch, 1:50) before primary antibody incubation was performed to reduce
non-specific signal. Imaging was performed using a Zeiss Axio Imager Z1 micro-
scope with an AxioCam MRm camera attachment running AxioVision software
release 4.8 (Carl Zeiss).
Duolink in situ analysis. Cryosections were processed as for immunofluorescence,
up to and including Fab fragment treatment and incubation with primary anti-
bodies. Duolink was performed as per manufacturer’s instructions (Olink
Bioscience) using anti-rabbit PLUS and anti-mouse MINUS PLA probes and
Orange detection reagents. Imaging was performed using a Zeiss Axio Imager Z1
microscope with an AxioCam MRm camera attachment running AxioVision
software release 4.8.
Whole-embryo in situ hybridization. RNA in situ hybridization on whole-
embryo was performed on E11.5 embryos fixed with 4% formaldehyde solution. In
brief, embryos were treated with proteinase K for 30 min and post-fixed with 4%
formaldehyde solution and 0.2% glutaraldehyde. The embryos were then incubated
with digoxigenin (DIG)-labelled riboprobes transcribed from cDNA-containing
plasmids at 65 C overnight. In the next day, the embryos went through stringent
washes in decreasing concentrations of saline-sodium citrate buffer. The DIG probe
was then detected with anti-DIG-alkaline phosphatase (AP) Fab fragment (Sigma-
Aldrich) by incubating at 4 C overnight. Colour was developed by incubating
embryos in BM Purple (AP substrate; Sigma-Aldrich) at pH9.5 until the pattern
was clear. The plasmid encoding Wt1 was kindly provided by Mathilda Mom-
mersteeg (Oxford, UK).
Cell culture. HEK293 cells (ATCC CRL-1573) were cultured in DMEM/F12þ
Glutamax supplemented with 10% FCS and 1% penicillin-streptomycin (Life
Technologies); SW13 cells (ATCC CLL-105) were cultured in Leibovitz L-15 (Life
Technologies) supplemented with 10% FBS and penicillin-streptomycin; mouse
primary epicardial cells were culture in DMEMþGlutamax supplemented with
10% heat-inactivated FCS, 1% streptomycin (Life Technologies), insulin-transfer-
rin-selenium (Biosource) and 10 units ml 1 mouse gamma interferon (Pepro-
Tech). Cells were maintained in a humidified atmosphere of 5% CO2 at 37 C
(HEK293 and SW13 cells) or 33 C (mouse primary epicardial cells) and were
passaged at 80–90% confluence using 0.05% trypsin (Life Technologies). All cell
lines used in this study have been routinely tested and found to be negative for
mycoplasma contamination.
Protein extraction. To prepare protein samples from cells for co-immunopreci-
pitation and/or sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS–PAGE), cells were lysed in 150 mM NaCl; 20 mM Tris–HCl pH 7.5; 1%
Triton X-100; 2 mM EDTA; 1 protein inhibitor cocktail (Roche). Lysates were
incubated on ice for 20 min, centrifuged at 16,000g at 4 C, and supernatants
prepared for the relevant application. To prepare protein samples from adult hearts
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for SDS–PAGE, hearts were collected and snap frozen before being manually
powdered in liquid nitrogen using a pestle and mortar. The powdered tissue was
transferred into a pre-cooled 1.5 ml tube and lysed in 1 ml of RIPA buffer (50 mM
Tris–HCl pH 7.6; 150 mM NaCl; 1% NP-40 (Calbiochem); 0.5% sodium deox-
ycholate; 0.1% SDS; 1 Protease Inhibitor Cocktail (Roche); 1 mM PMSF (Sigma);
1 mg ml 1 aprotinin (Sigma)) using a 21G needle and 1 ml syringe. Samples were
left to incubate on ice for 30 min, with vortexing every 10 min, and then centrifuged
at 16,000g for 20 min. Supernatants were then prepared for SDS–PAGE by the
addition of 2 Laemmli sample buffer (125 mM Tris pH 6.8; 4% SDS; 25%
glycerol; 0.1% bromophenol blue; 5% b-mercaptoethanol) and boiling at 95 C for
5 min.
Co-Immunoprecipitation and immunoblotting. For the co-IP experiments
(Fig. 4a,b), HEK293 cells were transfected using Polyfect Transfection Reagent
(Qiagen). Approximately 2.4 106 cells were seeded into 100 mm tissue culture
dishes and transfected 24 h later with 8 mg of Tb4–EGFP–N3 and 80 ml Polyfect.
After 48 h of post-transfection, cells were lysed as detailed above and 750 ml of
lysate was used for immunoprecipitation (IP) using Dynabeads Protein G (Invi-
trogen), as per manufacturer’s instructions but with amendments to the incubation
times. Antibodies used for IP were: Brg1-H88 (Santa Cruz); Tb4 (Immundiag-
nostik); control Rabbit IgG (Abcam). Briefly, 3 mg antibody diluted in 200ml
PBSþ 0.02% Tween-20 were added to 50 ml Dynabeads and incubated with rota-
tion for 2 h at room temperature. Beads were separated using a DynaMag-2 magnet
(Invitrogen) and washed once with PBSþ 0.02% Tween-20. Lysates were added to
the antibody-bound beads and incubated with rotation overnight at 4 C. The
beads were washed 4 times with PBS and suspended in 20 ml 2 Laemmli sample
buffer (125 mM Tris pH 6.8; 4% SDS; 25% glycerol; 0.1% bromophenol blue; 5%
b-mercaptoethanol) boiled at 95 C for 5 min and the supernatant collected and
analysed by SDS–PAGE. Lysate not used for IP (‘INPUT’) was processed for SDS-
PAGE by the addition of 2 Laemmli sample buffer and boiling at 95 C for
5 min. The original uncropped images of gels are shown in Supplementary Fig. 11.
Western blotting (Supplementary Fig. 1b) was performed using standard
SDS–PAGE methods using HRP-conjugated secondary antibodies and enhanced
chemiluminescence detection (both GE Heathcare). The original uncropped images
of gels are shown in Supplementary Fig. 12.
Dual luciferase assays. Transfection of SW13 cells for luciferase assays was
performed using Lipofectamine-2000 (Invitrogen) as per manufacturer’s
instructions. Briefly, 1 105 cells were seeded into 24 well plates in antibiotics-free
medium, and transfected 24 h later with 0.8 mg DNA, comprising 0.45 mg firefly
luciferase in pREP4, 0.05 mg TK-Renilla luciferase in pREP7 and 0.3 mg test DNA
(when transfecting 2 test constructs, a 1:1 ratio was used; when using only 1 test
construct, the remaining DNA was made up with empty pCI vector, which also
acted as ‘control’ DNA) and 2 ml Lipofectamine-2000. Cells were lysed 48 h post-
transfection and processed for the Dual-Luciferase Reporter Assay System (Pro-
mega), as per manufacturer’s instructions. The ratio of Firefly:Renilla luminescence
was used to compare samples. All transfections and subsequent readings were
performed in triplicate.
DNA constructs and plasmids. Sanger sequencing (Source Bioscience) was per-
formed on all DNA constructs. Tb4-EGFP-N3: using a full-length cDNA of Tb4 in
pcDNA3.1 as template DNA, PCR was performed using primers that added a
Kozak sequence and EcoRI site to the 50 end and a flexible glycine-serine linker and
BamHI site to the 30 end of the Tb4 open-reading frame (ORF). PCR was carried
out using Pfu polymerase (Promega). The PCR product was digested with EcoRI
and BamHI and ligated into pEGFP-N3 using T4 ligase (Promega). For NLS-Tb4-
myc/pcDNA3: NLS-Tb4-myc was synthesized by Eurofins MWG Operon and
inserted into pcDNA3. For  0.2 kb-luc/pREP4: pREP4-luc was provided by Keji
Zhao (NIH, Bethesda). Wt1767-luc/pGL2 Basic – a 767 bp sequence of the mouse
Wt1 promoter spanning  513 to þ 254 nucleotides relative to the transcription
initiation site was provided by Holger Scholz (Berlin). Using Wt1767-luc/pGL2
Basic as template, ECR  0.2 kb was amplified using PCR with primers that added
a BglII site to the 50 end and an XhoI site to the 30 end (NB. same primers as used
for ChIP-qPCR (Supplementary Table 3), but relevant restriction sites were
inserted in the forward and reverse sequences to allow cloning of ECR). PCR was
carried out using Pfu polymerase. The PCR amplicon was purified, digested and
was ligated to pREP4-luc. For  42 bp-luc/pREP4: using Wt1767-luc/pGL2 Basic as
template, ECR  42 bp was amplified using PCR with primers that added a BglII
site to the 50 end and an XhoI site to the 30 end (NB. same primers as used for
ChIP-qPCR (Supplementary Table 3), but relevant restriction sites were inserted in
the forward and reverse sequences to allow cloning of ECR). PCR was carried out
using Pfu polymerase. The PCR amplicon was purified and digested with BglII and
XhoI and was ligated to pREP4-luc. For þ 4.0 kb-luc/pREP4: using Wt1 intron
1/pGL3 Basic as template (Christoph Englert, Jena), the intrinsic ECR þ 4.0 kb was
amplified using PCR primers that added a KpnI site to the 50 end and an XbaI site
to the 30 end (NB. same primers as used for ChIP-qPCR (Supplementary Table 3),
but relevant restriction sites were inserted in the forward and reverse sequences to
allow cloning of ECR). PCR was carried out using Pfu polymerase. The SV40
promoter from pGL3-promoter was excised by sequential XhoI and HindIII
digestion, with the XhoI site blunted using T4 polymerase (Invitrogen), and ligated
into the promoterless pREP4-luc, cut sequentially with NotI and HindIII, with the
NotI site blunted using T4 polymerase. ECR þ 4.0 kb was digested with KpnI and
XbaI and ligated into SV40 promoter-pREP4-luc cut with KpnI and NheI, thereby
placing ECR þ 4.0 kb upstream of the SV40 promoter. For þ 5.8 kb-luc/pREP4:
using Wt1 intron 1/pGL3 Basic as template, the intrinsic ECR þ 5.8 kb was
amplified using PCR primers that added a NheI site to the 50 end and a BglII site to
the 30 end (NB. same primers as used for ChIP-qPCR (Supplementary Table 3), but
relevant restriction sites were inserted in the forward and reverse sequences to
allow cloning of ECR). PCR was carried out using Pfu polymerase. The PCR
amplicon was digested with BglII and NheI and ligated into pGL3-Promoter, also
cut with BglII and NheI, thereby placing ECR þ 5.8 kb upstream of the SV40
promoter. ECR þ 5.8 kb—together with the vector’s SV40 promoter and
luciferase—was then excised from pGL3-promoter using NheI and SalI and ligated
into pREP4 (now depleted of its luciferase). For TKRenilla/pREP7: the Renilla
luciferase under control of the TK promoter was cut from pRL-TK (Promega) by
sequential BglII and BamHI digestion, with the BglII site blunted using T4 poly-
merase and ligated into pREP7 (Invitrogen) cut sequentially with XbaI and BamHI,
with the XbaI site blunted using T4 polymerase, thereby removing pREP7’s RSV
promoter. Brg1/pCI: human Brg1 in pCI was a kind gift from Anthony Imbalzano
(Worcester, MA). Brm/pCI: human Brm in pCI was a kind gift from Samisubbu
Naidu (Indianapolis, IN).
Generation of Wt1 ECR-lacZ transgenic mice. In vivo validation of Wt1  42 bp,
þ 4.0 Kb and þ 5.8 Kb ECRs activity was done using an established mouse
transgenic system30, where a vector containing the cloned ECR (see DNA
constructs and Plasmids), a Hsp68 basal promoter and a b-galactosidase gene
(LacZ) is integrated into the mouse genome via standard pronuclear injection of
oocytes. Embryos were collected at E11.5 and stained for b-galactosidase (b-gal)
activity (see below). Integration of LacZ transgenes was further confirmed by PCR
analysis.
b-Galactosidase staining. For b-galactosidase (b-gal) staining embryos were
collected at E11.5, fixed on ice for 30 min in 2% formaldehyde solution containing
0.2% glutaraldehyde (both Sigma), washed twice with phosphate-buffered solution
(PBS) on ice, and stained overnight at room temperature in X-gal staining solution
containing 4 mM K4Fe(CN)6, 4 mM K3Fe(CN)6, 2 mM MgCl2 and 1 mg ml 1
X-gal (dissolved in N-dimethylformamide; Sigma).
RNA isolation and gene expression profile by qRT-PCR. For postnatal heart
samples, total RNA was isolated using Trizol reagent (Invitrogen), according to the
manufacturer’s instructions. For fetal hearts or cells, total RNA was isolated using
RNeasy Micro Kit (Qiagen), according to the manufacturer’s instructions. Total
RNA was reverse-transcribed using oligo dT primers and Superscript III RT
(Invitrogen). Real-time RT-PCR analysis was performed on an ABI 7900 Sequence
Detector (Applied Biosystems) using SYBR Green (QuantitectTM SYBR Green
PCR Kit, Qiagen). Data were normalized to Hprt or 18S (RNA stability assay)
expression. Fold-change in gene expression was determined by the 2DDCT
method and is presented relative to levels in sham, E11.5, E12.5 or control siRNA
samples. Primer sequences are listed in Supplementary Table 3. Statistical differ-
ences were detected using a two-tailed Student’s t-test.
Chromatin immunoprecipitation. Chromatin was prepared from fetal and post-
natal hearts (intact and post-MI). Hearts were dissected in chilled PBS; minced and
fixed with 1% formaldehyde solution at room temperature, and quenched with
0.125 M glycine before washing twice with PBS supplemented with protease
inhibitors (Protease Inhibitor Cocktail Tablet (Roche), 1 mM PMSF (Sigma) and
1 mg ml 1 aprotinin (Sigma)). Cells were then lysed (10 mM EDTA, 50 mM Tris–
HCl (pH 8.0), 1% SDS, protease inhibitors). Chromatin was sonicated to generate
fragment sizes of 500–1000 bp, and immunoprecipitated using antibodies listed in
Supplementary Table 4. Isolation of immunoprecipitated chromatin was done
according to manufacturer’s protocol (Millipore). The amount of specific immu-
noprecipitated DNA was then quantified by qPCR (see above) using primers
specific for each individual ECR sequence (and, as such, able to distinguish between
the different DNA sequences enriched by antibody pull-down), with each reaction
performed in triplicate (primers sequence used in ChIP-qPCR are included in
Supplementary Table 3). Signals from individual ChIP reactions were used to
calculate the % recovery of a given DNA segment relative to the total input signal.
Fold enrichment was determined as the fold-change in per cent of input (ChIP
signal/input signal) at the target regions (Wt1 ECRs)47. For the data presented in
Fig. 3 however, fold enrichment values are presented as the fold-change over the
level of ChIP with negative control IgG antibody (ChIP signal/IgG signal) to allow
comparison between control (co) and mutant (mut) samples.
ChIP-sequencing. Brg1 ChIP-seq was performed on PBS- and Tb4-primed,
injured-adult hearts (biological duplicates) collected four days after MI. Briefly,
tissues were cross-linked with 1% formaldehyde at room temperature for 10 min,
incubated in nuclei extraction buffer first, then in lysis buffer and sonicated.
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Solubilized chromatin was incubated overnight at 4 C with a specific rabbit
polyclonal anti-Brg1 antibody (Millipore; Supplementary Table 4) coupled to anti-
rabbit IgG Dynabeads (Invitrogen). Immunoprecipitated chromatin was then
purified by standard phenol-chlorophorm extraction and DNA libraries were
prepared with the NEBNext Ultra DNA Library Prep Kit for Illumina according to
the manufacturer’s protocol. Libraries were quantified with Qubit dsDNA HS
Assay Kit (Invitrogen) and KAPA Library Quantification Kit for Illumina, and then
sequenced on an Illumina NextSeq 500 instrument. Sequence reads were mapped
with Bowtie (version 1.0.0), using-m 2-X 2000 parameter, to the mouse reference
genome (mm9), obtained from the UCSC genome browser. Peaks were called using
MACS2 (version 2.0.10) using bdgcomp function. Genes closest to peaks were
determined using Bedtools (version 2.17.0). Bigwig files were generated using an
enhanced perl script (courtesy of Dr Jim Hughes, Weatherhall Institute of Mole-
cular Medicine, University of Oxford, UK). Plots were made using ChiPSeeker
R/Bioconductor package48.
Sequential ChIP. After primary ChIP, specific immunoprecipitates were washed,
eluted, incubated with 10 mM dithiothreitol at 37 C for 30 min, diluted 10 times in
ChIP buffer (10 mM EDTA, 50 mM Tris–HCl (pH 8.0), 1% SDS, protease
inhibitors) and re-immunoprecipitated with the secondary antibodies. Isolation of
re-immunoprecipitated chromatin was done according to manufacturer’s protocol
(Millipore). Extracted DNA was used for qPCR (see above). Fold enrichment was
determined as the fold-change in per cent IgG (ChIP signal/IgG signal) at the target
regions47,49.
siRNA experiments. siRNA sequences targeting Brg1 and C/EBPb transcripts
(Silencer Select Pre-designed siRNA from Ambion) were transfected into mouse
primary epicardial cells using Lipofectamine 2000 (Life Technologies) according to
the manufacturer’s instructions.
Statistical analysis. Animal numbers and sample sizes reflected the minimal
number needed for statistical significance based on previous experience. For MI
studies, hearts showing no morphological signs of infarct (for example, tissue
blanching around the ligating suture) at the stage of sample collection were
excluded from further analysis. No randomization or blinding was used. Statistics
were calculated using Microsoft Excel and Prism Graphpad software. The statistical
significance between two groups was determined using two-tailed Student’s t-test
(Microsoft Excel), and the data were reported as mean±s.d. Among three or more
groups (for example, data shown in Supplementary Fig. 9), one-way analysis of
variance (ANOVA) followed up by Tukey’s multiple comparison test was used for
comparisons (Prism Graphpad software). A value of Po0.05 was considered
statistical significant.
Data availability. The ChIP-seq data that support the findings of this study have
been deposited in Gene Expression Omnibus (GEO) with the accession number
GSE76239. All other relevant data are available from the corresponding authors on
reasonable request.
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